You are here

Article Text

Article menu

This article has a correction. Please see:

Download PDFPDF
PostScript
Letter
Is it safe to use remdesivir in combination with a combined p-glycoprotein and CYP3A4 inhibitor?
  1. Ömer Faruk Bahçecíoğlu,
  2. Selim Gök,
  3. Mefküre Durmuş
  1. Clinical Pharmacy, Inonu University, Malatya, Turkey
  1. Correspondence to Ömer Faruk Bahçecíoğlu, Clinical Pharmacy, İnönü Üniversitesi, Malatya, Turkey; omerfb92{at}hotmail.com

https://doi.org/10.1136/ejhpharm-2021-002680

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) was detected in Wuhan, China about 1 year ago and caused a pandemic that has been ongoing for about 10 months. Optimal antiviral therapy has not yet been established in the treatment of coronavirus disease 2019 (COVID-19) caused by this virus.

    Remdesivir is one of the most commonly used antiviral drugs in the treatment of COVID-19 worldwide. Remdesivir, a prodrug, converts to its active phosphate form and inhibits RNA-dependent RNA polymerase that enables the replication of the SARS-CoV-2.1 In vitro studies have demonstrated that remdesivir is a substrate for the cytochrome P450 (CYP450) enzymes CYP3A4, CYP2D6 and CYP2C8, as well as …

    View Full Text

    Footnotes

    • Correction notice This article has been corrected since it first published. The provenance and peer review statement has been included.

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

    • Competing interests None declared.

    • Provenance and peer review Not commissioned; internally peer reviewed.

    Linked Articles